Although GLP-1R agonists are not yet approved solely for treating MASH, major society guidelines and consensus statements have incorporated GLP-1R agonists in treatment pathways [10, 183]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.